RETATRUTIDE (10mg)

Retatrutide 10mg (LY3437943), a triple receptor agonist for metabolic research. (99%) Purity verified here on Australian soil at The University of Melbourne.

Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly that acts as an agonist at three distinct receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple agonist profile distinguishes it from dual agonists like tirzepatide.

The peptide structure enables extended duration of action through albumin binding, supporting less frequent administration in research protocols. Retatrutide is currently under investigation in Phase 3 clinical trials, representing one of the most advanced multi-receptor agonists in development.

Research has examined Retatrutide’s effects on glucose homeostasis, energy expenditure, and body composition through its coordinated actions on all three receptor systems. Studies have investigated how the addition of glucagon receptor agonism to GLP-1/GIP activity affects metabolic parameters compared to dual agonists.

The glucagon receptor agonist component is proposed to increase energy expenditure and hepatic fat oxidation, complementing the appetite-suppressing and insulin-sensitising effects mediated through GLP-1 and GIP receptors respectively.

Note: Retatrutide is an investigational compound not approved by any regulatory agency including the FDA or TGA. It is supplied strictly for research purposes.

Gen Ex Peptides supplies Retatrutide tested at an Australian university laboratory not generic overseas certificates. Each batch is verified for purity (99%) using HPLC and mass spectrometry.